Compare EL & ALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EL | ALC |
|---|---|---|
| Founded | 1946 | 1945 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Ophthalmic Goods |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.9B | 38.8B |
| IPO Year | 1995 | N/A |
| Metric | EL | ALC |
|---|---|---|
| Price | $105.05 | $79.71 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 11 |
| Target Price | ★ $95.05 | $89.96 |
| AVG Volume (30 Days) | ★ 3.4M | 2.1M |
| Earning Date | 10-30-2025 | 11-11-2025 |
| Dividend Yield | ★ 1.36% | 0.28% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.10 |
| Revenue | ★ $14,446,000,000.00 | $10,185,000,000.00 |
| Revenue This Year | $7.34 | $5.79 |
| Revenue Next Year | $4.07 | $7.36 |
| P/E Ratio | ★ N/A | $37.34 |
| Revenue Growth | N/A | ★ 4.34 |
| 52 Week Low | $48.37 | $71.55 |
| 52 Week High | $105.78 | $99.20 |
| Indicator | EL | ALC |
|---|---|---|
| Relative Strength Index (RSI) | 68.23 | 57.13 |
| Support Level | $102.15 | $78.55 |
| Resistance Level | $105.78 | $81.69 |
| Average True Range (ATR) | 2.86 | 1.24 |
| MACD | 1.39 | 0.09 |
| Stochastic Oscillator | 97.17 | 71.34 |
Estée Lauder is a leader in the global prestige beauty market, participating across skin care (49% of fiscal 2025 sales), makeup (29%), fragrance (17%), and hair care and others (5%), with top-selling brands such as Estée Lauder, Clinique, M.A.C, La Mer, Jo Malone London, Aveda, Bobbi Brown, and Origins. The firm operates in more than 150 countries, generating 31% of revenue from the Americas, 37% from Europe, the Middle East and Africa (including travel retail), and 32% from Asia-Pacific. Estée Lauder sells its products through department stores, travel retail, specialty multibrand beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.